Beranda › Limfoma Burkitt › Massachusetts › Boston
Uji klinis Limfoma Burkitt di Boston, MA
10 studi untuk Limfoma Burkitt mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- Dana-Farber Cancer Institute, Boston
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Menerima pesertaFase 3
- Dana-Farber Cancer Institute, Boston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Menerima pesertaFase 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 1
- Tufts Medical Center, Boston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- Beth Israel Deaconess Medical Center, Boston
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Menerima pesertaFase 1
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Menerima pesertaFase 2
- Floating Hospital for Children at Tufts Medical Center, Boston
- Dana Faber Cancer Institute/ Boston Children's Hospital, Boston
Uji klinis Limfoma Burkitt di kota lain
- Houston, TX21 studi
- Milwaukee, WI16 studi
- Philadelphia, PA16 studi
- New York City, NY14 studi
- Chicago, IL14 studi
- Cincinnati, OH12 studi
- Atlanta, GA12 studi
- Seattle, WA11 studi
- Durham, NC10 studi
- Aurora, CO10 studi
- Los Angeles, CA10 studi
- Kansas City, MO10 studi
Studi lain di Boston
- Kanker Payudara111 studi
- Kanker Paru Non-Sel Kecil90 studi
- Kanker (semua jenis)86 studi
- Kanker Kolorektal63 studi
- Kanker Metastatik63 studi
- Kanker Paru62 studi
- Kanker Ovarium61 studi
- Kanker Prostat59 studi
- Depresi52 studi
- Kanker Endometrium50 studi
- Gagal Jantung44 studi
- Leukemia Mieloid Akut44 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.